Viking Therapeutics Shares Surge as Rival Stumbles in Obesity Drug Race
Published on 02/25/2026 at 05:32 | Redaktion boerse-global.de
Shares of Viking Therapeutics experienced their most significant single-day advance in weeks on Monday, February 23, climbing approximately 11% to close at $34.39. The catalyst for this rally originated not from within Viking but from a major clinical setback suffered by its competitor, Novo Nordisk.
The Danish pharmaceutical giant reported disappointing Phase 3 trial results for its obesity treatment, CagriSema. In the REDEFINE 4 study, the combination of cagrilintide and semaglutid failed to meet its non-inferiority goal against Eli Lilly's tirzepatide. Over an 84-week period, CagriSema achieved an average weight loss of 20.2%, compared to 23.6% for tirzepatide. This news triggered a sharp decline in Novo Nordisk's stock, which fell over 16% to hit a 52-week low.
For Viking and other developers of GLP-1-based obesity therapies, the stumble by CagriSema suggests one fewer competitor in the race for regulatory approval and future market share.
Financial Position and Pipeline Progress
Viking Therapeutics concluded 2025 with a strong cash position of $706 million. However, the company's research and development expenditures have risen substantially. Fourth-quarter 2025 R&D costs reached $153.5 million, a significant increase from $31.0 million in the same period the prior year. For the full year 2025, R&D spending totaled $345.0 million, up from $101.6 million in 2024.
The net loss for Q4 2025 was $157.7 million, or $1.38 per share, compared to a net loss of $35.4 million, or $0.32 per share, in the fourth quarter of 2024.
The company's lead candidate, VK2735—a dual GLP-1 and GIP receptor agonist—is advancing through two parallel Phase 3 programs. The VANQUISH-1 trial, investigating subcutaneous administration in adults with obesity, has completed patient recruitment. The VANQUISH-2 study, which includes patients with obesity and type 2 diabetes, is nearing full enrollment.
A key differentiator for Viking is its development of an oral formulation of VK2735. Following feedback from the U.S. Food and Drug Administration (FDA) in late December 2025, the company plans to initiate an oral Phase 3 study in the third quarter of 2026. This dual-approach strategy sets Viking apart in the competitive GLP-1/GIP segment.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Promising data from the Phase 2 VENTURE study, published in the journal Obesity in January, demonstrated weight loss of up to 14.7% after 13 weeks of subcutaneous treatment, with no evidence of a plateau effect within that timeframe.
Beyond its lead program, Viking is preparing to submit an Investigational New Drug (IND) application for a novel amylin agonist in the first quarter of 2026. Additionally, a study investigating a maintenance dosing regimen is underway, with results anticipated in Q3 2026.
Stock Performance and Competitive Landscape
On Tuesday, February 24, the equity gave back a portion of its prior gains, trading down about 2% to approximately $33.76. The stock's 52-week range spans from $18.92 to $43.15. With roughly 115.6 million shares outstanding, Viking commands a market capitalization of around $3.6 billion.
The coming year is set to be eventful for the biotech firm. Key milestones include the maintenance dosing data readout and the initiation of the oral Phase 3 trial, both scheduled for the third quarter.
The competitive environment in the GLP-1 market continues to intensify, with candidates like Kailera's ripudapatid and Roche's CT-388 also in Phase 3 development. Nevertheless, the recent difficulties encountered by Novo Nordisk's CagriSema underscore that even established pharmaceutical leaders face no guarantee of success in this complex therapeutic area.
Ad
Viking Therapeutics Stock: New Analysis - 25 February
Fresh Viking Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
